Responses
Regular and young investigator award abstracts
Clinical trials in progress
389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
